Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California (Reuters) - Gilead Sciences ...

Shares of Jounce Therapeutics JNCE were up 21.2% on Mar 27 after management announced that the company entered into an agreement with Concentra Biosciences (“Concentra”) wherein the former will ...

- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host ...

While the tough funding environment has forced many biotechs to lay off staff or pare back their pipelines, Jounce has at least found a way to make some easy money in the process. The biotech has sold ...

The Board of Directors of Jounce Therapeutics Inc (NASDAQ: JNCE) confirmed that Concentra Biosciences LLC made an unsolicited and non-binding proposal to acquire 100% of the equity of Jounce. Tang ...

It ain’t over ‘til it’s over and for Redx Pharma, it’s over. Redx and Jounce Therapeutics announced Monday morning that the two companies agreed to terminate their proposed business combination ...

There’s significant change on the way at Jounce Therapeutics. The embattled clinical-stage company announced Wednesday afternoon that it is laying off more than half of its workforce as part of a ...

Shares of Jounce Therapeutics (JNCE +0.00%) jumped more than 39% last month, according to data from S&P Global Market Intelligence. The development-stage company reported full-year 2018 operating ...

Will the biotech IPO market be better in 2017? Cambridge, Massachusetts-based Jounce Therapeutics hopes so. A low-key filing on Dec. 30 with the Securities and Exchange Commission (SEC) shows the ...

Jounce Therapeutics (NASDAQ:JNCE) is merging with U.K.-based Redx Pharma in an all stock deal after which the combined company will be known as Redx and listed on Nasdaq under the ticker REDX. The ...